门诊环境下细菌与病毒生物标志物即时检测的诊断准确性
这项诊断研究于2019年10月至2021年4月纳入门诊(急诊科、紧急护理和初级保健)中年龄≥1岁、有症状且72小时内发热的急性呼吸道感染(ARI)患者及无症状对照,用指尖血进行FebriDx即时免疫分析,10分钟读取结果,临床医生和裁定者对结果盲法。在496例有最终诊断的ARI患者中,参考标准分类为细菌相关反应73例(14.7%)、病毒相关反应296例(59.7%)、阴性127例(25.6%)。FebriDx对细菌感染分类的敏感性为93.2%(95%CI 84.9%-97.0%)、特异性88.4%(95%CI 85.0%-91.1%)、阳性预测值58.1%(95%CI 49.1%-66.7%)、阴性预测值98.7%(95%CI 96.9%-99.4%);对病毒感染分类的敏感性70.3%(95%CI 64.8%-75.2%)、特异性88.0%(95%CI 82.8%-91.8%)、阳性预测值89.7%(95%CI 85.1%-92.9%)、阴性预测值66.7%(95%CI 60.8%-72.1%)。作者认为该快速诊断试验的性能可能为临床医生评估ARI症状的细菌或病毒病因提供参考。
要点
- 在496例有最终诊断的ARI患者中,FebriDx分类细菌感染的敏感性93.2%(95%CI 84.9%-97.0%)、特异性88.4%(95%CI 85.0%-91.1%)。
- FebriDx分类细菌感染的阴性预测值98.7%(95%CI 96.9%-99.4%),阳性预测值58.1%(95%CI 49.1%-66.7%)。
- FebriDx分类病毒感染的敏感性70.3%(95%CI 64.8%-75.2%)、特异性88.0%(95%CI 82.8%-91.8%)、阳性预测值89.7%(95%CI 85.1%-92.9%)、阴性预测值66.7%(95%CI 60.8%-72.1%)。
- 参考标准下,496例有最终诊断的ARI患者中细菌相关反应73例(14.7%)、病毒相关反应296例(59.7%)、阴性127例(25.6%)。
- 该研究纳入门诊(急诊科、紧急护理和初级保健)中年龄≥1岁、有症状且72小时内发热的ARI患者,指尖血检测10分钟读取结果。
适用人群与场景
- 纳入标准:门诊环境(即急诊科、紧急护理和初级保健)中有症状、年龄1岁或以上、疑似急性呼吸道感染(ARI)且72小时内发热的患者;另设无症状对照组。
- 排除标准:免疫抑制状态,或近期疫苗、抗生素、卒中、手术、大面积烧伤或心肌梗死。
诊断标准与关键阈值
- 细菌或病毒相关全身宿主反应由预先设定的比较算法经裁定分类确定。
处置流程与药物剂量
- 使用指尖血进行细菌和病毒免疫分析检测,10分钟读取结果,治疗临床医生和裁定者对结果盲法。
研究设计与关键结果
- 研究类型:诊断研究;纳入708人(520例ARI患者、170例无ARI患者、18人退出),最终分析496例有最终诊断的ARI患者。
- 人群特征:520例ARI患者中男性230例(44.2%)、女性290例(55.8%),平均(SD)年龄35.3(17.7)岁;24例(4.6%)因实验室信息缺失被分类为未知。
- 参考标准分类:496例有最终诊断者中细菌相关反应73例(14.7%)、病毒相关反应296例(59.7%)、阴性127例(25.6%)。
- 细菌感染分类性能:敏感性93.2%(95%CI 84.9%-97.0%,68/73),特异性88.4%(95%CI 85.0%-91.1%,374/423),阳性预测值58.1%(95%CI 49.1%-66.7%,68/117),阴性预测值98.7%(95%CI 96.9%-99.4%,374/379)。
- 病毒感染分类性能:敏感性70.3%(95%CI 64.8%-75.2%,208/296),特异性88.0%(95%CI 82.8%-91.8%,176/200),阳性预测值89.7%(95%CI 85.1%-92.9%,208/232),阴性预测值66.7%(95%CI 60.8%-72.1%,176/264)。
证据类型、等级与局限
- 证据类型:诊断研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该快速诊断试验的性能可能为临床医生评估ARI症状的细菌或病毒病因提供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute respiratory infections (ARIs) account for most outpatient visits. Discriminating bacterial vs viral etiology is a diagnostic challenge with therapeutic implications.
OBJECTIVE: To investigate whether FebriDx, a rapid, point-of-care immunoassay, can differentiate bacterial- from viral-associated host immune response in ARI through measurement of myxovirus resistance protein A (MxA) and C-reactive protein (CRP) from finger-stick blood.
DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study enrolled adults and children who were symptomatic for ARI and individuals in a control group who were asymptomatic between October 2019 and April 2021. Included participants were a convenience sample of patients in outpatient settings (ie, emergency department, urgent care, and primary care) who were symptomatic, aged 1 year or older, and had suspected ARI and fever within 72 hours. Individuals with immunocompromised state and recent vaccine, antibiotics, stroke, surgery, major burn, or myocardial infarction were excluded. Of 1685 individuals assessed for eligibility, 259 individuals declined participation, 718 individuals were excluded, and 708 individuals were enrolled (520 patients with ARI, 170 patients without ARI, and 18 individuals who dropped out).
EXPOSURES: Bacterial and viral immunoassay testing was performed using finger-stick blood. Results were read at 10 minutes, and treating clinicians and adjudicators were blinded to results.
MAIN OUTCOMES AND MEASURES: Bacterial- or viral-associated systemic host response to an ARI as determined by a predefined comparator algorithm with adjudication classified infection etiology.
RESULTS: Among 520 participants with ARI (230 male patients [44.2%] and 290 female patients [55.8%]; mean [SD] age, 35.3 [17.7] years), 24 participants with missing laboratory information were classified as unknown (4.6%). Among 496 participants with a final diagnosis, 73 individuals (14.7%) were classified as having a bacterial-associated response, 296 individuals (59.7%) as having a viral-associated response, and 127 individuals (25.6%) as negative by the reference standard. The bacterial and viral test correctly classified 68 of 73 bacterial infections, demonstrating a sensitivity of 93.2% (95% CI, 84.9%-97.0%), specificity of 374 of 423 participants (88.4% [95% CI, 85.0%-91.1%]), positive predictive value (PPV) of 68 of 117 participants (58.1% [95% CI, 49.1%-66.7%), and negative predictive value (NPV) of 374 of 379 participants (98.7% [95% CI, 96.9%-99.4%]).The test correctly classified 208 of 296 viral infections, for a sensitivity of 70.3% (95% CI, 64.8%-75.2%), a specificity of 176 of 200 participants (88.0% [95% CI, 82.8%-91.8%]), a PPV of 208 of 232 participants (89.7% [95% CI, 85.1%-92.9%]), and an NPV of 176 of 264 participants (66.7% [95% CI, 60.8%-72.1%]).
CONCLUSIONS AND RELEVANCE: In this study, a rapid diagnostic test demonstrated diagnostic performance that may inform clinicians when assessing for bacterial or viral etiology of ARI symptoms.
参考来源
- Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Netw Open. 2022. PMID: 36255727. doi:10.1001/jamanetworkopen.2022.34588
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。